for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

139.50USD

Change

0.00(0.00%)

Volume

58,259

Today's Range

--

 - 

--

52 Week Range

3.65

 - 

189.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Novavax Appoints Gregory Covino As CFO And Announces Leadership Updates

Nov 9 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX APPOINTS GREGORY F. COVINO AS CHIEF FINANCIAL OFFICER AND ANNOUNCES LEADERSHIP UPDATES.NOVAVAX INC - JOHN TRIZZINO, CHIEF BUSINESS OFFICER, TAKES ON ADDITIONAL ROLE AS CHIEF COMMERCIAL OFFICER.NOVAVAX INC - FILIP DUBOVSKY, M.D. PROMOTED TO EXECUTIVE VICE PRESIDENT, CHIEF MEDICAL OFFICER.

Novavax Reports Q3 Rev Of $157 Million Versus $2.5 Million

Nov 9 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX REPORTS THIRD QUARTER 2020 FINANCIAL AND OPERATIONAL RESULTS.Q3 LOSS PER SHARE $3.21.Q3 REVENUE $157 MILLION VERSUS $2.5 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.73 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $230.6 MILLION -- REFINITIV IBES DATA.SECURED ADDITIONAL LARGE-SCALE MANUFACTURING FOR NVX-COV2373 WITH EXPECTED GLOBAL CAPACITY OVER TWO BILLION DOSES BY MID-2021.FOR NVX-COV2373 U.K. PHASE 3 INTERIM DATA EXPECTED AS SOON AS EARLY Q1 2021.RESEARCH AND DEVELOPMENT EXPENSES INCREASED TO $294.1 MILLION IN Q3 OF 2020, COMPARED TO $18.6 MILLION IN SAME PERIOD IN 2019.QTRLY RESEARCH AND DEVELOPMENT EXPENSES INCLUDE EXPENSE OF $187.2 MILLION ASSOCIATED WITH MANUFACTURING SUPPLY AGREEMENTS FOR NVX-COV2373.NOVAVAX - AS OF SEPT 30, HAD $571.6 MILLION IN CASH, EQUIVALENTS, MARKETABLE SECURITIES & RESTRICTED CASH, VERSUS $82.2 MILLION AS OF DEC 31, 2019.

Novavax COVID-19 Vaccine Granted Fast Track Designation By U.S. FDA

Nov 9 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX COVID-19 VACCINE GRANTED FAST TRACK DESIGNATION BY U.S. FDA.NOVAVAX INC - NOVAVAX EXPECTS TO BEGIN ITS PIVOTAL PHASE 3 CLINICAL TRIAL IN UNITED STATES AND MEXICO BY END OF NOVEMBER.NOVAVAX INC - DEPENDING ON OVERALL COVID-19 ATTACK RATE, INTERIM DATA IN UK TRIAL, WHICH IS ALSO EVENT-DRIVEN, ARE EXPECTED AS SOON AS EARLY Q1 2021.NOVAVAX INC - ONGOING PHASE 3 TRIAL IN UK TO EVALUATE NVX-COV2373 IS EXPECTED TO BE FULLY ENROLLED BY THE END OF NOVEMBER.

Novavax And Commonwealth Of Australia Announce Agreement In Principle For Acquisition Of Novavax Covid-19 Vaccine

Nov 4 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX AND COMMONWEALTH OF AUSTRALIA ANNOUNCE AGREEMENT IN PRINCIPLE FOR ACQUISITION OF NOVAVAX COVID-19 VACCINE.NOVAVAX AND COMMONWEALTH OF AUSTRALIA ANNOUNCE AGREEMENT IN PRINCIPLE FOR ACQUISITION OF NOVAVAX COVID-19 VACCINE.NOVAVAX - HEADS OF TERMS PROVIDES FOR DELIVERY OF NVX-COV2373 TO AUSTRALIA STARTING AS EARLY AS FIRST HALF OF 2021.NOVAVAX INC - ANNOUNCED SIGNING OF A NON-BINDING HEADS OF TERMS DOCUMENT WITH AUSTRALIAN GOVERNMENT.NOVAVAX - VACCINE REGIMEN IS EXPECTED TO REQUIRE TWO DOSES PER INDIVIDUAL, ADMINISTERED 21 DAYS APART.NOVAVAX INC - AGREEMENT TO SUPPLY 40 MILLION DOSES OF CO'S COVID-19 VACCINE CANDIDATE, NVX-COV2373.

Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

Oct 27 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX PROVIDES PHASE 3 COVID-19 VACCINE CLINICAL DEVELOPMENT UPDATE.NOVAVAX INC - FULL ENROLLMENT EXPECTED BY END OF NOVEMBER.NOVAVAX INC - EVENT-DRIVEN INTERIM DATA EXPECTED AS SOON AS EARLY Q1 2021.NOVAVAX INC - 5,500 VOLUNTEERS ENROLLED TO DATE IN PIVOTAL PHASE 3 CLINICAL TRIAL IN U.K..NOVAVAX INC - U.S. PIVOTAL PHASE 3 CLINICAL TRIAL PLANNED TO BEGIN BY END OF NOVEMBER.NOVAVAX INC - SIGNIFICANT PROGRESS IN LARGE-SCALE MANUFACTURING ACHIEVED WITH SOME DELAY FROM ORIGINAL TIMELINE.NOVAVAX INC - EXPECTS PIVOTAL CLINICAL TRIAL TO BEGIN IN UNITED STATES AND MEXICO BY END OF NOVEMBER.NOVAVAX - TO PRESENT DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL, INCLUDING NEW PHASE 2 REACTOGENICITY DATA, DURING PUBLIC CDC ACIP MEETING ON OCT. 30.NOVAVAX INC - PIVOTAL PHASE 3 STUDY EXPANDED TO 15,000 PARTICIPANTS.

Novavax Appoints Leadership Team To Advance Nanoflu Through Regulatory Licensure

Oct 13 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX APPOINTS LEADERSHIP TEAM TO ADVANCE NANOFLU THROUGH REGULATORY LICENSURE.NOVAVAX INC - TEAM WILL FOCUS ON GLOBAL NANOFLU LICENSURE AND EVALUATION OF POST-PANDEMIC INFLUENZA/COVID-19 COMBINATION VACCINE WITH NVX-COV2373.NOVAVAX INC - RUSSELL (RIP) WILSON PROMOTED TO EXECUTIVE VICE PRESIDENT AND NANOFLU GENERAL MANAGER.NOVAVAX INC - INTENDS TO SEEK REGULATORY APPROVAL FROM FDA FOR NANOFLU UNDER ACCELERATED APPROVAL PATHWAY PREVIOUSLY GRANTED TO COMPANY.

Endo Announces Fill-Finish Manufacturing And Services Agreement For Novavax Covid-19 Vaccine Candidate

Sept 25 (Reuters) - Endo International PLC <ENDP.O>::ENDO ANNOUNCES FILL-FINISH MANUFACTURING AND SERVICES AGREEMENT FOR NOVAVAX COVID-19 VACCINE CANDIDATE.ENDO INTERNATIONAL PLC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..ENDO INTERNATIONAL PLC - PAR STERILE'S ROCHESTER FACILITY HAS BEGUN PRODUCTION OF NVX-COV2373 FINAL DRUG PRODUCT.ENDO INTERNATIONAL PLC - INTERIM DATA FOR TRIALS IS EXPECTED BEFORE END OF 2020.ENDO INTERNATIONAL PLC - PAR STERILE WILL ALSO FILL-FINISH NVX-COV2373 VACCINE INTENDED FOR COMMERCIAL DISTRIBUTION IN UNITED STATES..

Novavax Initiates Phase 3 Efficacy Trial Of COVID-19 Vaccine In The United Kingdom

Sept 24 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX INITIATES PHASE 3 EFFICACY TRIAL OF COVID-19 VACCINE IN THE UNITED KINGDOM.NOVAVAX INC - CLINICAL TRIAL TO ENROLL UP TO 10,000 VOLUNTEERS ACROSS UK TO ASSESS WHETHER NVX-COV2373 IS EFFECTIVE IN PREVENTION OF COVID-19.NOVAVAX - TRIAL IS EXPECTED TO ENROLL AND IMMUNIZE UP TO 10,000 INDIVIDUALS BETWEEN 18-84 YRS OF AGE OVER NEXT FOUR TO SIX WEEKS.NOVAVAX INC - PHASE 3 EFFICACY TRIAL OF COVID-19 VACCINE IN UNITED KINGDOM DESIGNED TO ENROLL AT LEAST 25 PERCENT OF PARTICIPANTS OVER AGE OF 65.NOVAVAX INC - UP TO 400 PARTICIPANTS WILL ALSO RECEIVE A LICENSED SEASONAL INFLUENZA VACCINE AS PART OF A CO-ADMINISTRATION SUB-STUDY.NOVAVAX INC - HAS CONTINUED TO SCALE-UP ITS MANUFACTURING CAPACITY, CURRENTLY AT UP TO 2 BILLION ANNUALIZED DOSES.NOVAVAX INC - TRIAL OF COVID-19 VACCINE IN UK TO PRIORITIZE GROUPS THAT ARE MOST AFFECTED BY COVID-19, INCLUDING RACIAL AND ETHNIC MINORITIES.NOVAVAX INC - PHASE 3 EFFICACY TRIAL OF COVID-19 TRIAL HAS TWO PRIMARY ENDPOINTS.NOVAVAX INC - INTERIM ANALYSIS WILL BE PERFORMED WHEN 67% OF DESIRED NUMBER OF CASES HAS BEEN REACHED.

Novavax Announces COVID-19 Vaccine Manufacturing Agreement With Serum Institute Of India

Sept 15 (Reuters) - Novavax::NOVAVAX ANNOUNCES COVID-19 VACCINE MANUFACTURING AGREEMENT WITH SERUM INSTITUTE OF INDIA.NOVAVAX INC - SERUM INSTITUTE OF INDIA TO MANUFACTURE ABOUT 1 BILLION DOSES OF NVX-COV2373 IN 2021.NOVAVAX INC - SIIPL AGREEMENT INCREASES GLOBAL MANUFACTURING CAPACITY FOR NVX-COV2373 TO OVER 2 BILLION ANNUALIZED DOSES WHEN AT FULL CAPACITY IN 2021.

Novavax And Canada Reach Agreement In Principle To Acquire Novavax’ Covid-19 Vaccine

Aug 31 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX AND CANADA REACH AGREEMENT IN PRINCIPLE TO ACQUIRE NOVAVAX’ COVID-19 VACCINE.NOVAVAX INC - REACHED AN AGREEMENT IN PRINCIPLE WITH GOVERNMENT OF CANADA TO SUPPLY UP TO 76 MILLION DOSES OF NVX-COV2373, NOVAVAX' COVID-19 VACCINE.NOVAVAX - CO, CANADA EXPECT TO FINALIZE ADVANCE PURCHASE AGREEMENT UNDER WHICH CO WILL SUPPLY DOSES OF NVX-COV2373 TO CANADA BEGINNING AS EARLY AS Q2 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up